grant
Development and validation of an autologous mouse model for the study of immune interactions with glioblastoma
Organization UNIVERSITY OF PENNSYLVANIALocation PHILADELPHIA, UNITED STATESPosted 3 Jun 2024Deadline 31 May 2029
NIHUS FederalResearch GrantFY2025AddressAllogenicAnimal ModelAnimal Models and Related StudiesAnimalsAreaAutologousB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBiologic ModelsBiological ModelsBiologyBlood Precursor CellBone-Derived Transforming Growth FactorBrain NeoplasiaBrain NeoplasmsBrain TumorsCAR T cell therapyCAR T cellsCAR T therapyCAR modified T cellsCAR-TCAR-TsCD34CD34 geneCell BodyCell TherapyCellsCellular immunotherapyCharacteristicsChemokine Receptor GeneClinicClinical ResearchClinical StudyClinical TrialsCytometryCytotoxic cellDNA mutationDataDevelopmentEngraftmentEnsureEnvironmentEvaluationExhibitsFOXP3FOXP3 geneForkhead Box P3FutureGenetic ChangeGenetic defectGenetic mutationGlioblastomaGoalsGrade IV Astrocytic NeoplasmGrade IV Astrocytic TumorGrade IV AstrocytomaGvHDHPCA1Hematopoietic Progenitor CellsHematopoietic stem cellsHeterograftHeterologous TransplantationHomologous Wasting DiseaseHumanHuman Cell LineImmuneImmune mediated therapyImmune responseImmune systemImmunesImmunocompetentImmunodeficient MouseImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyImplantIndividualInfusionInfusion proceduresInstitutionJM2K lymphocyteLeadLiquid substanceLymphoidLymphoid CellMacrophageMediatingMiceMice MammalsMilk Growth FactorModel SystemModelingModern ManMurineMusMutationMyeloid CellsMφNK CellsNatural Killer CellsOrganoidsOutcomePD 1PD-1PD1PatientsPb elementPennsylvaniaPlatelet Transforming Growth FactorPlayPre-Clinical ModelPreclinical ModelsReagentRegulatory T-LymphocyteRoleRunt DiseaseSCURFINSamplingSignal PathwaySolid NeoplasmSolid TumorSourceStudy modelsSystemT cell infiltrationT cells for CART-CellsT-LymphocyteTGF BTGF-betaTGF-βTGFbetaTGFβTestingTherapeuticTransforming Growth Factor betaTransforming Growth Factor-Beta Family GeneTranslatingTregTumor TissueUniversitiesUpregulationValidationWorkXenograftXenograft procedureXenotransplantationbench bed sidebench bedsidebench to bed sidebench to bedsidebench to clinicbench to clinical practiceblood cell progenitorblood progenitorblood stem cellblood-forming stem cellcancer microenvironmentcell based interventioncell mediated immune responsecell mediated interventioncell mediated therapiescell typecell-based immunotherapycell-based therapeuticcell-based therapycellular therapeuticcellular therapychemokine receptorchimeric antigen T cell receptorchimeric antigen receptor (CAR) T cell therapychimeric antigen receptor (CAR) T cellschimeric antigen receptor Tchimeric antigen receptor T cell therapychimeric antigen receptor T cellschimeric antigen receptor T therapychimeric antigen receptor fusion protein T-cellschimeric antigen receptor modified T cellsdevelopmentalexhaustexperienceexperimentexperimental researchexperimental studyexperimentsfluidgenome mutationglioblastoma multiformegraft versus host diseasegraft vs host diseasegraft vs. host diseaseheavy metal Pbheavy metal leadhematopoietic progenitorhematopoietic stem progenitor cellhemopoietic progenitorhemopoietic stem cellhost responsehumanized micehumanized mousehypoimmunityimmune cell therapyimmune check pointimmune checkpointimmune competentimmune deficiencyimmune microenvironmentimmune suppressionimmune suppressive activityimmune suppressive functionimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmunecheckpointimmuno therapyimmunodeficiencyimmunoresponseimmunosuppressive activityimmunosuppressive functionimmunosuppressive microenvironmentimmunosuppressive responseimmunosuppressive tumor microenvironmentin vivoinfusionsliquidmodel developmentmodel developmentsmodel of animalmouse modelmurine modelnovelpre-clinicalpre-clinical developmentpre-clinical researchpreclinicalpreclinical developmentpreclinical researchprogrammed cell death 1programmed cell death protein 1programmed death 1programsregulatory T-cellsresponsesle2social rolespongioblastoma multiformesystemic lupus erythematosus susceptibility 2telomerethymus derived lymphocytetranscriptomicstumortumor growthtumor immune microenvironmenttumor microenvironmenttumor-immune system interactionstumors in the brainvalidationsxeno-transplantxeno-transplantation
Description preview
Project Summary
An adaptive immunosuppressive microenvironment is a major barrier to immune-based therapies for solid
tumors, including glioblastoma (GBM). Current model systems for preclinical development either lack substantial
components of the immune system or rely upon different species’ immune systems, which display significant
differences…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click